ARTIMPLANT INTERIM REPORT JANUARY - MARCH 2009

ARTIMPLANT INTERIM REPORT JANUARY - MARCH 2009

Västra Frölunda, Sweden, May 5, 2009

• Net revenue for the first quarter amounted to SEK 4.8 million (2.1)*
• The net loss for the first quarter totaled SEK 4.5 million (6.2)  
• Earnings per share for the first quarter amounted to SEK -0.08 (-0.10)
• Sales of Artelon® Spacer totaled SEK 3.5 million (1.3) 
• Sales of Artelon® Tissue Reinforcement amounted to SEK 1.3 million (0.8)
• Spacer agreements with Small Bone Innovations have been made non-exclusive and
Artimplant's margin per unit sold has increased significantly

Events after the period-end
• The Schulthess Clinic in Zurich has been granted clearance by Swissmedic to
commence a clinical investigation of treatment of lumbar facet joints using an
Artelon® implant.
• The agreement with Biomet Sports Medicine has been revised, giving Artimplant
a better margin in return for responsibility for clinical market studies.

N.B. This is a translation from Swedish. The Swedish version shall always take
precedence.

Artimplant will present this report at the Annual Meeting on May 5, 2009, at
5pm, Central European Time (GMT+1). The presentation will be published on the
Company's website after the meeting. No telephone conference will be held by
reason of this report. For further information and full interim report see
www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information is available at www.artimplant.com. To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on May 5, 2009 at 3 PM (GMT+1).